ACADIA Pharmaceuticals

Both products exhibit high list pricing and strong net pricing power typical of first‑in‑class CNS and rare‑disease drugs. DAYBUE’s initial U.S. WAC was reported near 21.10 dollars per mL, implying very high annual cost by patient weight, with payer management evolving; FDA orphan status reduces near‑term direct competition.

However, tolerability can limit real‑world persistence, capping effective pricing power. NUPLAZID’s pricing is solid in neurology but is subject to Medicare IRA inflation rebates, which already impacted 4Q25 results. Net, pricing power is strong today but has policy guardrails and adherence limits.